You are here

Commercial Availability for Lunesta Delayed

MARLBOROUGH, Mass., Jan. 11 /PRNewswire-FirstCall/ -- Sepracor Inc. (NASDAQ:SEPR) today announced a revision to the anticipated commercial availability of LUNESTA(TM) brand eszopiclone for the treatment of insomnia.

On December 15, 2004, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for LUNESTA for the treatment of insomnia. As expected, the FDA recommended that LUNESTA, like all other non-benzodiazepine hypnotics, be classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA).

The Federal government's administrative process for formally classifying LUNESTA as a Schedule IV controlled substance is not yet complete. Because of uncertainties regarding marketing the product prior to completion of scheduling, Sepracor's plan to make LUNESTA commercially available in early January 2005 is no longer feasible. Sepracor is currently working diligently with the FDA and DEA to resolve these uncertainties and conclude final administrative actions related to the scheduling of LUNESTA.

At this time, Sepracor anticipates that LUNESTA will be available to patients nationwide within the first quarter of 2005.

"All commercial activities, including manufacturing, supply chain and sales and marketing required for a successful launch, are firmly in place," said W. James O'Shea, President and Chief Operating Officer at Sepracor.

Source: Sepracor Inc.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs